Novocure completes enrollment in Phase 3 TRIDENT trial for newly diagnosed glioblastoma; data expected 2026

NovoCure Ltd

Final patient enrolled in global Phase 3 TRIDENT trial (950 patients) evaluating Optune Gio concurrent with radiation + temozolomide for newly diagnosed GBM.
Patients randomized to TTFields + TMZ + radiation vs TMZ + radiation for 6 weeks, then all receive standard care (TTFields + maintenance TMZ).
Primary endpoint is overall survival; secondary endpoints include PFS, safety, quality of life, and radiological response.
Top-line data from the trial is anticipated in 2026; enrollment began in December 2020.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.